Plasma lipids metabolism in mild cognitive impairment and Alzheimer's disease

Imagem de Miniatura
Arquivos
art_COSTA_Plasma_lipids_metabolism_in_mild_cognitive_impairment_and_2019.PDF (1.02 MB)
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
Citação
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, v.20, n.3, p.190-196, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: Expression of phospholipids and related molecules could provide panels of multiple biomarkers searching for the signature of Alzheimer's disease (AD). The aim of the present study was to quantify ten phospholipids and simultaneously determine phospholipase A(2) (PLA(2)) activity in blood of mild cognitive impairment (MCI) and AD patients. Methods: Thirty-four AD, 20 MCI and 25 controls were enrolled. The phospholipids where analysed using the AbsoluteIDQp180 Kit. PLA(2) activities were accessed in platelets by a radio-enzymatic assay. Results: The study failed to fix the ten phospholipids as a panel to predict AD; the levels of PCaaC36:6, PCaaC40:6 and C16:1-OH were lower in MCI than in controls (P = 0.041, P = 0.012, P = 0.044 respectively). PCaaC40:2 levels were lower in MCI than in AD (P = 0.041). The converters MCI-AD showed at baseline lower levels of PCaaC40:2 (P = 0.050) and PCaaC40:6 (P = 0.037) than controls. iPLA(2) activity was reduced in AD and MCI than in controls (P < 0.001). We found positive correlation in the control group between PCaaC38:6 and tPLA(2) (r = 0.680; P = 0.001) and sPLA(2) (r = 0.601; P = 0.004); PCaaC40:1 and iPLA(2) (r = 0.503; P = 0.020); PCaaC40:6 and tPLA(2) (r = 0.532; P = 0.013) and sPLA(2) (r = 0.523; P = 0.015). Conclusions: Lipids metabolites in plasma might indirectly indicate changes in neuronal membrane and this deregulation can outline the transition between healthy and diseased brains.
Palavras-chave
Phospholipids, phospholipase A2 activity, Alzheimer's disease, mild cognitive impairment and biomarkers
URI
https://observatorio.fm.usp.br/handle/OPI/32525
Referências
  1. Ahmad W, 2013, MOL NEUROBIOL, V47, P399, DOI 10.1007/s12035-012-8352-z
  2. Bjorkqvist M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029868
  3. Blennow K, 2004, J INTERN MED, V256, P224, DOI 10.1111/j.1365-2796.2004.01368.x
  4. Cordeiro Q, 2010, ARQ NEURO-PSIQUIAT, V68, P189, DOI 10.1590/S0004-282X2010000200007
  5. DENNIS EA, 1994, J BIOL CHEM, V269, P13057
  6. Dennis EA, 2011, CHEM REV, V111, P6130, DOI 10.1021/cr200085w
  7. Eckert GP, 2011, PHARMACOPSYCHIATRY, V44, P161, DOI 10.1055/s-0031-1279731
  8. Eckert GP, 2010, CURR PROTEIN PEPT SC, V11, P319, DOI 10.2174/138920310791330668
  9. Fiandaca MS, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00237
  10. FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
  11. Fonteh AN, 2013, J LIPID RES, V54, P2884, DOI 10.1194/jlr.M037622
  12. Forlenza Orestes V, 2015, Alzheimers Dement (Amst), V1, P455, DOI 10.1016/j.dadm.2015.09.003
  13. Forlenza OV, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-89
  14. Gattaz WF, 2014, J NEURAL TRANSM, V121, P193, DOI 10.1007/s00702-013-1088-8
  15. Gattaz WF, 1996, EUR ARCH PSY CLIN N, V246, P129, DOI 10.1007/BF02189113
  16. GATTAZ WF, 1995, BIOL PSYCHIAT, V37, P13, DOI 10.1016/0006-3223(94)00123-K
  17. Gaudin M, 2012, BIOANALYSIS, V4, P2153, DOI 10.4155/BIO.12.189
  18. Goh WWB, 2017, TRENDS BIOTECHNOL, V35, P498, DOI 10.1016/j.tibtech.2017.02.012
  19. Gonzalez-Dominguez R, 2014, J PROTEOMICS, V104, P37, DOI 10.1016/j.jprot.2014.01.014
  20. Grimm MOW, 2011, J CHROMATOGR A, V1218, P7713, DOI 10.1016/j.chroma.2011.07.073
  21. Horrobin DF, 2003, PHOSPHOLIPID SPECTRU
  22. Humpel C, 2011, TRENDS BIOTECHNOL, V29, P26, DOI 10.1016/j.tibtech.2010.09.007
  23. Ibanez C, 2013, J CHROMATOGR A, V1302, P65, DOI 10.1016/j.chroma.2013.06.005
  24. Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004
  25. Klavins Kristaps, 2015, Alzheimers Dement (Amst), V1, P295
  26. Klein J, 2000, J NEURAL TRANSM, V107, P1027, DOI 10.1007/s007020070051
  27. Kosicek M, 2013, INT J MOL SCI, V14, P1310, DOI 10.3390/ijms14011310
  28. Lambeau G, 2008, ANNU REV BIOCHEM, V77, P495, DOI 10.1146/annurev.biochem.76.062405.154007
  29. Lee JCM, 2011, J NEUROCHEM, V116, P813, DOI 10.1111/j.1471-4159.2010.07033.x
  30. Li NJ, 2010, CLIN BIOCHEM, V43, P992, DOI 10.1016/j.clinbiochem.2010.04.072
  31. Mapstone M, 2014, NAT MED, V20, P415, DOI 10.1038/nm.3466
  32. Marksteiner J, 2011, NEUROBIOL AGING, V32, P539, DOI 10.1016/j.neurobiolaging.2009.03.011
  33. MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
  34. Mulder C, 2003, J NEURAL TRANSM, V110, P949, DOI 10.1007/s00702-003-0007-9
  35. Olazaran J, 2015, J ALZHEIMERS DIS, V45, P1157, DOI 10.3233/JAD-142925
  36. Oresic M, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.55
  37. Perttu EK, 2012, J AM CHEM SOC, V134, P4485, DOI 10.1021/ja210989h
  38. Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x
  39. PONS R, 1995, J CHILD NEUROL, V10, pS2, DOI 10.1177/0883073895010002S03
  40. Proitsi P, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.127
  41. Ray S, 2007, NAT MED, V13, P1359, DOI 10.1038/nm1653
  42. Reuter SE, 2012, CLIN PHARMACOKINET, V51, P553, DOI 10.2165/11633940-000000000-00000
  43. ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698
  44. Schaeffer EL, 2005, PSYCHOPHARMACOLOGY, V181, P392, DOI 10.1007/s00213-005-2256-9
  45. Schaeffer EL, 2008, PSYCHOPHARMACOLOGY, V198, P1, DOI 10.1007/s00213-008-1092-0
  46. Schaeffer EL, 2011, PROG NEURO-PSYCHOPH, V35, P1612, DOI 10.1016/j.pnpbp.2011.05.001
  47. Schaeffer EL, 2010, PROG NEURO-PSYCHOPH, V34, P1381, DOI 10.1016/j.pnpbp.2010.08.019
  48. Schaeffer EL, 2009, PSYCHOPHARMACOLOGY, V202, P37, DOI 10.1007/s00213-008-1351-0
  49. Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003
  50. Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200
  51. Tajima Y, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-68
  52. Talib LL, 2015, EUR ARCH PSY CLIN N, V265, P701, DOI 10.1007/s00406-015-0600-6
  53. Talib LL, 2012, PROSTAG LEUKOTR ESS, V86, P149, DOI 10.1016/j.plefa.2012.02.005
  54. Whiley L, 2014, NEUROBIOL AGING, V35, P271, DOI 10.1016/j.neurobiolaging.2013.08.001
  55. Wood PL, 2014, NEUROPSYCHOPHARMACOL, V39, P24, DOI 10.1038/npp.2013.167

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/27